To evaluate the effect of disease activity on accrual damage.

**Methods:** A retrospective study was carried out from January 2010 to December 2018. Clinical records of patients with SLE (ACR criteria 1982/97) were reviewed considering baseline visit as the first clinical or control visit of 2010. For subsequent visits, data were collected annually until 2018. SLE activity was defined for each visit according to GLADEL’s definition: 1- Remission Without Treatment (RwT); SLEDAI 0, without prednisone or immunosuppressive drugs (IS); 2- Remission on Treatment (RoT); SLEDAI 0, prednisone up to 5mg/day or immunosuppressive drugs in maintenance doses; 3- LDAS (Low Disease Activity Status): SLEDAI ≤ 4, prednisone up to 7.5mg/ ay and/or IS in maintenance doses; 4- Non-Optimal Activity Control (NOC): SLEDAI > 4, prednisone > 7.5mg/ day and/or IS in induction dose. The use of hydroxychloroquine was allowed for all groups. For the analysis, patients who remained in remission (with and without treatment) or LDAS for at least 75% of the follow-up time were grouped and compared with patients who remained active during that same period. Demographic, laboratory, treatment related variables and death were studied. Accrual damage was assessed with SLICC / SDI. Patients with less than two annual visits were excluded.

Statistical analysis: descriptive measures, Test T, Mann Whitney, Chi2 Test, Fisher’s exact test, bivariate correlation, logistic regression model with mixed effects.

**Results:** Two hundred eighty-five medical records were reviewed and 100 patients with SLE were included, 89% women, mean age at baseline visit 38.5 ± 12 years old and mean time of disease 9.3 ± 7.3 years. The average SLEDAI and SLICC/ SDI baseline scores were 3.7 and 0.8 respectively. The SLICC/ SDI score at last visit was 2.2 and the average SLICC/SDI change (∆SLICC) compared to baseline visit score was 1.4 ± 1.6.

The prevalence of patients who were in remission for at least 75% of the follow-up time was 38% (95% CI 26.8-50%). NOC patients categorized at baseline visit had the highest ∆SLICC (p 0.001). The ∆SLICC was significantly lower in patients who were at least 75% of the follow-up time in remission (p 0.01) or LDAS (p 0.01) compared to those with NOC. In the Logistic Regression Model, the change of the SLICC/SDI score was 2.9 times higher for the NOC group than for RwT.

**Conclusion:** The frequency of remission in this cohort of patients with SLE was 38%.

Worse control of disease activity, was associated with higher accumulated damage.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.6062

---

**FRI0608-HPR**

**FREQUENCY AND PATIENTS BELIEFS ON VACCINATION IN RHEUMATIC DISEASES**

M. Viola1, A. Benitez2, C. Garbarino1, G. Rodriguez1, F. Benavidez1, C. Peon1, E. S. Blanco1, H. Molina1, G. Gómez1, G. Redondo1, M. Delavega1, D. Mata1, A. Riopedre1, O. Messina1, Hospital General de Agudos Dr. Cosme Argerich, Ciudad Autónoma de Buenos Aires, Argentina

**Background:** Infectious diseases are increased in patients with rheumatic disorders; vaccine immunization improves morbidity and mortality.

**Objectives:** The aim of this study was to describe the frequency of vaccination in patients with rheumatic disorders and to compare the results with those obtained in 2009 and 2013 in a similar population. We also identified factors leading to lack of vaccination and patients beliefs on vaccines.

**Methods:** Multicentric cross sectional study in patients with autoinimmune diseases from external rheumatology offices. Evaluation of vaccination status and patients knowledge about vaccines were studied. A comparative analysis was carried out with the series registered in 2009 and 2013 in a similar population. We also identified factors leading to lack of vaccination and patients beliefs on vaccines.

**Results:** Two hundred eighty-five medical records were reviewed and 100 patients with SLE were included, 89% women, mean age at baseline visit 38.5 ± 12 years old and mean time of disease 9.3 ± 7.3 years. The average SLEDAI and SLICC/ SDI baseline scores were 3.7 and 0.8 respectively. The SLICC/ SDI score at last visit was 2.2 and the average SLICC/SDI change (∆SLICC) compared to baseline visit score was 1.4 ± 1.6.

The prevalence of patients who were in remission for at least 75% of the follow-up time was 38% (95% CI 26.8-50%). NOC patients categorized at baseline visit had the highest ∆SLICC (p 0.001). The ∆SLICC was significantly lower in patients who were at least 75% of the follow-up time in remission (p 0.01) or LDAS (p 0.01) compared to those with NOC. In the Logistic Regression Model, the change of the SLICC/SDI score was 2.9 times higher for the NOC group than for RwT.

**Conclusion:** The frequency of remission in this cohort of patients with SLE was 38%.

Worse control of disease activity, was associated with higher accumulated damage.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.6062

---

**FRID067-CHR**

**SEVERITY AND PREDICTORS OF PAIN INTENSITY AND HAND DISABILITY IN PATIENTS WITH TRAPEZIOMETACARPAL OSTEOARTHRITIS**

T. Hamasa1,2,3, P. Harris1,2,3, N. Bureau1,2,3, N. Gaudreau4,5, N. Patenaude1,2,3, M. Choinière3,4,5, CHUM Hospital (Université de Montréal), Montréal, Canada; 1Université de Montréal, Montréal, Canada; 2Centre de recherche du CHUM (CRCHUS), Montréal, Canada; 3Université de Sherbrooke, Sherbrooke, Canada; 4CHUS Hospital (Université de Sherbrooke), Sherbrooke, Canada

**Background:** Trapeziometacarpal osteoarthritis (TMO) is one of the most prevalent and painful forms of hand osteoarthritis. It limits thumb mobility, reduces hand functions, and manual activities. Yet, no study has exhaustively documented the characteristics of this pathology using a biopsychosocial approach (e.g., pain, disability, psychological well-being, pain-related catastrophic thinking, quality of life). Furthermore, radiographic TMO severity and osteoarthritis are only weakly to moderately correlated. The extent to which biopsychosocial factors (e.g., pain duration, depression, education) contribute to interindividual variability in TMO pain and hand disability merits further investigation.

**Objectives:** This study aimed at (1) describing the pain experience of patients with trapeziometacarpal osteoarthritis (TMO) from a biopsychosocial perspective, and (2) identifying predictors of their pain intensity and hand disability.

**Methods:** A total of 227 TMO patients recruited from 16 healthcare institutions completed validated questionnaires assessing their biopsychosocial characteristics. The associations of pain severity and hand disability with various biopsychosocial characteristics were analyzed by linear regression.

**Results:** The participants’ mean age was 62.6 ± 8.5 years and 78% were women. Their mean pain intensity on the average in the last seven days was 5.8 ± 2.1 while their hand disability scores averaged 45.4 ± 18.8 on the QuickDASH. In terms of health-related quality of life, the participants’ scores on the physical and mental summary scales of the SF-12v2 were 41.0 ± 9.4 and 48.7 ± 9.7 respectively. Results of the multivariable linear regression analyses revealed that age, living condition, pain intensity, pain-related catastrophic thinking, and depression levels accounted for 43.3% of the variance in pain intensity while age, sex, pain intensity, pain-related catastrophic thinking, depression, level of education, employment status and living condition accounted for 60.6% of the variance in hand function.

**Conclusion:** This comprehensive study showed that patients with TMO experience pain of moderate to severe intensity which can affect various aspects...
of their daily living and their physical health-related quality of life. Greater tendency to catastrophize in the face of pain and higher depression levels were associated with more severe pain suggesting that psychological interventions aiming at reducing these factors could be beneficial for some patients with TMO.

References:


Acknowledgments: This study was supported by a discretionary fund of the Centre de recherche du CHUM (CRCHUM) to Choinière and from the Multidisciplinary Council of the CHUM. Hamasaki was supported by a Doctoral training award of the Fonds de recherche du Québec—Santé, a doctoral scholarship from the CHUM Foundation to Harris (Hand Surgery Branch) and from Choinière’s internal funds of the CRCHUM.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.536